Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Only A Matter Of Time before Launching North of $ 0.01
s-and-no-reverse-split-301022343.html
Trans Global Group, Inc. Announces New Products and No Reverse Split[color=red][/color]
NEWS PROVIDED BY
Trans Global Group, Inc.
Mar 12, 2020, 09:46 ET
COCONUT CREEK, Florida, March 12, 2020 /PRNewswire/ -- Trans Global Group, Inc. (OTCPK: TGGI) would like to take this opportunity to bring all of its shareholders up-to-date on the Company and share some insights as to where the Company is headed over the course of 2020.
First off, we would like to confirm that TGGI management has no intention of filing for a reverse split of its Common stock. We are now in a position of financial health that will allow us to carry out what is needed for our plans in 2020.
We recently announced that beginning in April, TGGI will start receiving its $10,000 monthly payments from Global Consortium, Inc. The monthly payments will be increased starting in August to $16k per month, so the Company can collect the total amount owed of $120,000 in 2020. This new injection of cash will be reflected in our quarterly statements. The money collected will only be used to further the Company's business plan to begin generating revenue, not to pay any accrued wages.
TGGI spent the last year and half fine tuning its revolutionary device that could be used in the expanding cannabis edible market, alcohol market and several other uses. While also developing new a residual revenue stream similar to how the razor blade and k-cup markets operate. This device could very easily replace the vape pen that was hugely popular, allowing people to still get the benefit of Cannabis/CBD without any inhaling.
TGGI has a few paths it could follow, first by becoming a plastics manufacturer and shipping the unfilled products to vendors who could fill them and sell them or second by entering into license deals allowing for the use of its products. There is no single direction the Company needs to follow in order to roll out its product line, which has expended beyond the original 2 designs.
During this time the Company also worked with a chef to create a line of sauces that can be sold as plain or infused with CBD, THC or CBD-THC. These combinations give the company 20 different varieties to offer consumers and half of them can be sold online.
In the coming weeks the Company will have several announcements, that include new management and a series of acquisitions "Rollup" of a Global product that will be extremely beneficial to the devices.
The Company intends to have this completed during the month of April.
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
Contact:
Matt Dwyer
transglobalgroupinc@gmail.com
954-906-0098
SOURCE Trans Global Group, Inc.
[MISSING IMAGE: LG_ONCONOVATHERA-BW.JPG]
Onconova Therapeutics, Inc.
375 Pheasant Run
Newtown, PA 18940 USA
June 10, 2020
Dear Fellow Onconova Stockholder,
We cordially invite you to attend Onconova Therapeutics, Inc.’s (the “Company” or “Onconova”) Reconvened 2020 Annual Meeting of Stockholders to be held virtually at 10:30 a.m. Eastern Daylight Time on June 26, 2020 (the “Reconvened Annual Meeting”). The Reconvened Annual Meeting will focus on the proposal (“Proposal 7”) to approve an amendment to add 12.5 million shares to the Company’s 2018 Omnibus Incentive Compensation (the “2018 Plan”). The Reconvened Annual Meeting will be held via the Internet at www.virtualshareholdermeeting.com/ONTX2020 and instructions on how to participate and demonstrate proof of stock ownership are posted at www.virtualshareholdermeeting.com/ONTX2020 and on your proxy card.
At the time of the closing of the polls at the Company’s Annual Meeting held on May 27, 2020 (the “Annual Meeting”), votes in favor of Proposal 3, the proposal to add 25 million shares to the 2018 Plan, exceeded votes against. However, the Company subsequently learned from the Inspector of Election that additional votes had been cast but not tabulated, resulting in Proposal 3 not passing After considering feedback from stockholders, the Board of Directors approved Proposal 7 for stockholder consideration at the Reconvened Annual Meeting which is an Incentive Compensation Plan Amendment to add 12.5 million shares to the 2018 Plan, which represents a 50% decrease in the size of the requested increase in authorized shares at the Annual Meeting. The Board of Directors of the Company believes that the Incentive Compensation Plan Amendment is needed to enable the Company’s compensation program to remain competitive and enable the Company to attract and retain experienced, highly-qualified directors, employees, consultants and advisors who will contribute to the Company’s success; including leadership of a new commercial organization.
Based on stockholder feedback, if the Incentive Compensation Plan Amendment is approved by the stockholders, the Board of Directors also plans to have a portion of the incentive compensation awards be performance based that will vest based on performance criteria in order to align employee and stockholder interests. It is expected that a portion of near-term grants would vest based upon the Company’s clinical and regulatory progress.
BASED ON THE FOREGOING AND THE INFORMATION PROVIDED IN THE DEFINITIVE ADDITIONAL PROXY MATERIALS, THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” AMENDMENT 2020-1 TO THE ONCONOVA THERAPEUTICS, INC. 2018 OMNIBUS INCENTIVE COMPENSATION PLAN, AS AMENDED AND RESTATED (PROPOSAL 7)
Based on feedback from stockholders, the Board of Directors expects it will withdraw Proposal 2, the proposal to combine outstanding shares of Onconova’s common stock into a lesser number of outstanding shares, or a “reverse stock split” at the Reconvened Annual Meeting. Onconova expects to defer any reverse stock split until topline data from its pivotal Phase 3 “INSPIRE” trial are announced (expected during the second half of 2020), or as required by Nasdaq. If the Company has not achieved compliance with Nasdaq’s minimum bid price rules by August 17, 2020, the Company expects it will request a 6-month extension from Nasdaq in order to regain compliance with these rules.
375 Pheasant Runwww.onconova.comPhone: 267 759 3680
Newtown,PA
18940
Fax: 267 759 3681
ONTX Presenting - Jun 11 - 14, 2020 [color=red][/color]
25th Congress of the European Hematology Association (EHA25 Virtual): e-Poster Presentation
View Additional Information
Details will be provided in an upcoming Press Release
https://investor.onconova.com/events-and-presentations
"FROM THE COCKPIT "[color=red][/color]
https://www.plyzertechnologies.com/#fromcockpit
"03.06.2020 - Plyzer Technologies Spain SL is pleased to announce that it has signed a new customer for its Plyzer Intelligence platform: Bioiberica, founded in 1975 when they started to research and produce the active ingredient Heparin, an anticoagulant that saves more than 100 million lives every year."
Bioiberica is part of the SARIA Group, the leading international manufacturer of products for human health and consumption, animal nutrition and agriculture. The company boast a team of 400 professionals and are represented in over 65 countries. More information about Bioiberica can be found by visiting: https://www.bioiberica.com
"We are delighted to partner with Bioiberica, that has consolidated their name as an international benchmark for the research and production of pharmaceutical active ingredients. Data is everywhere and nowadays without being able to comprehend it and use it properly brands like Bioiberica can lose their competitiveness", said Luis Pallares, Founder of Plyzer Technologies Corporation."
https://www.plyzertechnologies.com/2020/03/plyzer-technologies-spain-sl-signs-the-global-life-science-company-bioiberica-as-a-new-saas-customer-for-its-business-analytics-platform-plyzer-intelligence/
Great Research !
" ITOX-Medtronic-100,000 Registrations For Ventilator Specifications + Collaboration With Space X & Dräger, GE Healthcare, Getinge, Hamilton Medical, Nihon Kohden, Philips, Vyaire Medical, and others, to form the Ventilator Training Alliance."
Medtronic receives over 100,000 registrations for ventilator specifications
With ~ 181 Pharmaceutical Products, AKRX Remains A Primary Acquisition Target For Oral as well as Nasal Co-Vid 19 Treatments "
https://www.akorn.com/prod_list_all.php
A
Acetaminophen and Codeine Phosphate Oral Solution, USP CV
Acetic Acid Otic Solution, USP
Acetylcysteine Injection
Acyclovir Oral Suspension, USP
Adenosine Injection, USP
AK-Fluor® (fluorescein injection, USP)
AK-POLY-BAC™ (bacitracin zinc and polymyxin B sulfate ophthalmic ointment, USP)
Akten® (lidocaine hydrochloride ophthalmic gel)
Albuterol Sulfate Inhalation Solution
Albuterol Sulfate Syrup
Alfentanil Hydrochloride Injection, USP CII
Amantadine Hydrochloride Oral Solution, USP
Amicar® (aminocaproic acid oral solution)
Amicar® (aminocaproic acid) Tablets
Aminocaproic Acid Tablets, USP
AnaSed® (xylazine sterile solution) Injection
Apraclonidine Ophthalmic Solution, USP
Artificial Tears Solution (polyvinyl alcohol ophthalmic solution)
Atropine Sulfate Ophthalmic Solution, USP
AzaSite® (azithromycin ophthalmic solution)
Azelastine Hydrochloride Nasal Spray
Azelastine Hydrochloride Ophthalmic Solution
Top ?
B
BAL In Oil™ (dimercaprol injection, USP)
Betamethasone Dipropionate Lotion, USP
Betaxolol Ophthalmic Solution, USP
Betimol® (timolol ophthalmic solution)
Brimonidine Tartrate Ophthalmic Solution
Bromfenac Ophthalmic Solution
Buprenorphine and Naloxone Sublingual Tablets CIII
Buprenorphine HCl Sublingual Tablets, CIII
Butorphic® CIV (butorphanol tartrate injection)
Top ?
C
Calcipotriene Topical Solution
Calcitriol lnjection, USP
Capastat® Sulfate (capreomycin for injection, USP)
Chlorothiazide Sodium for Injection, USP
Ciclopirox Topical Solution
Cimetidine Hydrochloride Oral Solution
Ciprofloxacin Ophthalmic Solution, USP
Clobetasol Propionate Cream, USP
Clobetasol Propionate Cream-Emollient
Clobetasol Propionate Gel
Clobetasol Propionate Ointment, USP
Clobetasol Propionate Shampoo
Clobetasol Propionate Topical Solution, USP
Cogentin® (benztropine mesylate injection)
Cosopt® (dorzolamide hydrochloride-timolol maleate ophthalmic solution)
Cosopt® PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%/0.5%
Cromolyn Sodium Ophthalmic Solution, USP
Cyclopentolate Hydrochloride Ophthalmic Solution, USP
Cyclopentolate Hydrochloride Ophthalmic Solution, USP (Formerly AK-Pentolate™)
Top ?
D
Dehydrated Alcohol Injection, USP
Desonide Ointment
Desoximetasone Ointment, USP
Dexmedetomidine Hydrochloride Injection
Diabetic Tussin® (Acetaminophen, Dextromethorphan HBr, Diphenhydramine HCl) NightTime Cold and Flu
Diabetic Tussin® (Dextromethophan and Guaifenasin) Maximum Strength Cough and Chest Congestion DM
Diabetic Tussin® (Dextromethophan HBr, Guaifenasin) Cough and Chest Congestion DM
Diabetic Tussin® (Dextromethorphan HBr and Guaifenesin) Maximum Strength Cough and Chest Congestion DM
Diabetic Tussin® (Guaifenesin) Chest Congestion
Diclofenac Sodium Ophthalmic Solution
Diclofenac Sodium Topical Gel
Dicyclomine Hydrochloride Injection, USP
Diltiazem Hydrochloride Injection
Docu Liquid (Docusate Sodium oral solution)
Dorzolamide Hydrochloride 2% and Timolol Maleate 0.5% Sterile Ophthalmic Solution in Single-use Containers - PRESERVATIVE FREE
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution
Dorzolamide Hydrochloride Ophthalmic Solution
Dronabinol Capsule, USP CIII
Top ?
E
Ephedrine Sulfate Injection, USP
Eptifibatide Injection, for Intravenous Use
Erythromycin Ophthalmic Ointment, USP
Esomeprazole Sodium for Injection
Ethosuximide Capsules, USP
Ethosuximide Oral Solution, USP
Top ?
F
Fentanyl Citrate Injection, USP CII
Ferrous Sulfate Drops
Ferrous Sulfate Elixir
Fluticasone Propionate Nasal Spray, USP
Ful-Glo® (fluorescein sodium ophthalmic strips, USP)
Top ?
G
Gabapentin Oral Solution
Gatifloxacin Ophthalmic Solution
Gentak® (gentamicin sulfate ophthalmic ointment, USP)
Gentamicin Sulfate Ophthalmic Solution
Gentamicin Sulfate Ophthalmic Solution, USP
Gonak™ (hypromellose ophthalmic demulcent solution)
Granisetron Hydrochloride Injection, USP
Guaiatussin AC Oral Liquid, CV
Guaifenesin Oral Solution
Top ?
H
HydrALAZINE Hydrochloride Injection, USP
Hydrocodone Bitartrate and Homatropine Methylbromide Syrup, CII
Hydrocortisone and Acetic Acid Otic Solution, USP
Hydromorphone Hydrochloride Injection, USP CII (High Potency Formulation)
Top ?
I
IC-Green® (indocyanine green for injection, USP)
Isoflurane Inhalation Agent, USP
Top ?
K
Ketorolac Tromethamine Ophthalmic Solution
Ketotifen Fumarate Ophthalmic Solution
Top ?
L
Labetalol Hydrochloride Injection, USP
Lactulose Solution, USP
Latanoprost Ophthalmic Solution
Levetiracetam Oral Solution
Levocarnitine Oral Solution, USP
Levocarnitine Tablets, USP
Levofloxacin Injection, for Intravenous Use
Levofloxacin Ophthalmic Solution
Levofloxacin Oral Solution
Lidocaine and Prilocaine Cream
Lidocaine Hydrochloride Jelly, USP
Lidocaine Hydrochloride Oral Topical Solution, USP
Lidocaine Ointment, USP
Lorazepam Oral Concentrate, USP CIV
Lortab® Elixir CII (hydrocodone bitartrate and acetaminophen oral solution)
Loteprednol Etabonate Ophthalmic Suspension
Lubricant Eye Drops
Lubricant Eye Ointment
Top ?
M
Mag-Ox® 400 Magnesium Dietary Supplement
Megestrol Acetate Oral Suspension, USP
Methadone Hydrochloride Injection, USP CII
Midazolam Injection, USP CIV
Morphine Sulfate Oral Solution, CII
Moxifloxacin Ophthalmic Solution, USP
Multi-betic® Specifically Formulated for People with Diabetes
Mycophenolate Mofetil for Injection, USP
Myorisan™ (isotretinoin capsules, USP)
Top ?
N
Naloxone Hydrochloride Injection, USP
Nembutal® Sodium Solution CII (pentobarbital sodium injection, USP)
Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP
Neomycin Sulfate Tablets, USP
Nystatin Oral Suspension, USP
Top ?
O
Ofloxacin Ophthalmic Solution, USP
Ofloxacin Otic Solution
Olopatadine Hydrochloride Ophthalmic Solution, USP
Ophthalmic Solution Eyewash
Ophthalmic Solution Eyewash Purified Water
Orphenadrine Citrate Injection, USP
Oxycodone Hydrochloride Oral Solution, USP CII
Top ?
P
Paremyd® (hydroxyamphetamine hydrobromide and tropicamide ophthalmic solution) 1%/0.25%
Phenylephrine Hydrochloride Ophthalmic Solution, USP
Physostigmine Salicylate Injection
Pilocarpine Hydrochloride Ophthalmic Solution, USP
PrednisoLONE Oral Solution, USP
Prednisolone Sodium Phosphate Oral Solution
Progesterone Capsules
Promethazine Hydrochloride and Codeine Phosphate Syrup CV
Promethazine Hydrochloride and Phenylephrine Hydrochloride Syrup
Promethazine Hydrochloride Oral Solution, USP
Promethazine Hydrochloride, Phenylephrine Hydrochloride and Codeine Phosphate Syrup, CV
Proparacaine Hydrochloride Ophthalmic Solution, USP
Pyrazinamide Tablets, USP
Top ?
R
Rifampin Capsules, USP
Ropivacaine Hydrochloride Injection, USP
Top ?
S
Sevoflurane Inhalation Agent
Sodium Chloride Ophthalmic Ointment, USP
Sodium Chloride Ophthalmic Solution, USP
Sodium Diuril® (chlorothiazide sodium)
Sufentanil Citrate Injection, USP CII
Sulfamethoxazole and Trimethoprim Oral Suspension, USP
Top ?
T
Tetracaine Hydrochloride Injection, USP
TheraTears® Dry Eye Therapy Lubricant Eye Drops (sodium carboxymethylcellulose) Preservative Free
TheraTears® Dry Eye Therapy Lubricant Eye Drops (Sodium Carboxymethylcellulose)
TheraTears® Eye Nutrition 1200 mg Omega-3 Supplement
TheraTears® Nighttime Dry Eye Therapy Lubricant Eye Gel (Sodium Carboxymethylcellulose) Preservative Free
TheraTears® SteriLid® Eyelids Cleanser
Timolol Maleate Ophthalmic Solution, USP
Tobramycin Inhalation Solution, USP
Tobramycin Ophthalmic Solution, USP
Tolazine® (tolazoline HCl injection, USP)
Triamcinolone Acetonide Topical Aerosol, USP
Trihexyphenidyl Hydrochloride Oral Solution, USP
Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution
Tropicamide Ophthalmic Solution, USP
Top ?
U
Uro-Mag® (magnesium oxide)
Top ?
V
Valproic Acid Oral Solution, USP
VetaKet® CIII (ketamine hydrochloride injection, USP)
Vitamin D Supplement Drops
Top ?
X
Xopenex® (levalbuterol HCI) Inhalation Solution
Xopenex® (levalbuterol HCI) Inhalation Solution Concentrate
Top ?
Y
Yobine® (yohimbine sterile solution) Injection
Top ?
Z
Zioptan® (tafluprost ophthalmic solution)
Zostrix® Maximum Strength Natural Foot Pain Relief Cream
Zostrix® Maximum Strength Natural Pain Relief Cream
Zostrix® Original Strength Natural Pain Relief Cream
This Spinal Procedure Highlights The Next Generation In Minimally Invasive Spine Surgery As Highlighted on OZOP Surgical OXSC: Website - http://ozopsurgical.com/. The 2019 Healthcare & Pharmaceutical Award can be viewed on Page # 67 https://www.ghp-news.com/issues/healthcare-pharmaceutical-awards-2019/67/#zoom=z As leader in developing minimally invasive medical devices to decrease both surgical time as well as recovery time, OZSC products http://ozopsurgical.com/ will be in demand. Silver + Remains Quite Possible.
The Medical $cience Propelling GRCK - Dr. Paul Dragul ENT Otolaryngologist
I believe that we are obsessed with the second, minute and daily stock price but lets view the larger horizon.
Medical Professionals over the years have witnessed the health benefits of ingesting CBD Oils and one considers if Dr. Paul, has treated many a patient over a 40 year time span to be convinced that the benefits of engaging in Cannabinoid Therapy's exceed the negative connotations or prosecution till recent North American Governments sanctioned such a prescription protocol.
Remember, all Doctors take the sacred Hippocratic Oath.....
https://en.wikipedia.org/wiki/Hippocratic_Oath
"First Do No Harm"
I swear to fulfill, to the best of my ability and judgment, this covenant:
I will respect the hard-won scientific gains of those physicians in whose steps I walk, and gladly share such knowledge as is mine with those who are to follow.
I will apply, for the benefit of the sick, all measures [that] are required, avoiding those twin traps of overtreatment and therapeutic nihilism.
I will remember that there is art to medicine as well as science, and that warmth, sympathy, and understanding may outweigh the surgeon's knife or the chemist's drug.
I will not be ashamed to say "I know not," nor will I fail to call in my colleagues when the skills of another are needed for a patient's recovery.
I will respect the privacy of my patients, for their problems are not disclosed to me that the world may know. Most especially must I tread with care in matters of life and death. If it is given me to save a life, all thanks. But it may also be within my power to take a life; this awesome responsibility must be faced with great humbleness and awareness of my own frailty. Above all, I must not play at God.
I will remember that I do not treat a fever chart, a cancerous growth, but a sick human being, whose illness may affect the person's family and economic stability. My responsibility includes these related problems, if I am to care adequately for the sick.
I will prevent disease whenever I can, for prevention is preferable to cure.
I will remember that I remain a member of society, with special obligations to all my fellow human beings, those sound of mind and body as well as the infirm.
If I do not violate this oath, may I enjoy life and art, respected while I live and remembered with affection thereafter. May I always act so as to preserve the finest traditions of my calling and may I long experience the joy of healing those who seek my help.
We all know medical professionals professionally and personally.
DR. Paul Dragul's Profile - Extended version..
https://health.usnews.com/doctors/paul-dragul-530748
As I believe there are more benevolent stockholders on this board as apposed to the malevolent who perpetually pummeling a company with negativity, I humbly submit that Dr. Paul Dragul is an ENT-Otolaryngologist https://health.usnews.com/doctors/paul-dragul-530748
specializing in Head and Neck Surgery including Ear, Nose and Throat regions of the human anatomy.https://en.wikipedia.org/wiki/Otorhinolaryngology
The Center of Disease Control reports that 480,000 deaths a year in the US, equating to 1 in 5, that can be directly attributed to Cigarette Smoking.
https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm
Although we all make choices in life and have to live with the consequences, I highly doubt that any company would engage the expertise of a 4 Decade Medical Surgeon if he has not witnessed the the improved quality of life for his patients.......
Perhaps, it is he we should thank for endeavoring to process and titrate CBD Oil down to a predictable and prescribed dosage while factoring in all pharmaceutical standards.
In Closing, I suspect that our good Doctor has seen more cancer than he would have ever wanted to witness or operate on.....and therefore I submit this last link from The National Library of Medicine entitled:
"A Users Guide To Cannabinoid Therapies In Oncology"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5176373/
Again, the true upwards trajectory of both patients and investors is $OON
JC799
GRCK - Liftoff and Landing On The Moon.
Shareholders are Here 10.04.2017.......
Agreed Sir. From Broken Arrow To Future GRCK $TOCK MI$$ILE Angle of Ascent from Ground To Air Optimized.
Today's GRCK Stock Action - Broken Arrow -
GRCK - Angle of Ascent In Price Per Share - 10.05.2017 - 10.10.2017
Thank-you goarmy2020 for your service on the GRCK Board and beyond...
In addition to Personal Freedom, I believe that we have a GRCK opportunity for Financial Freedom.
God Bless
JOECROWE799
JOECROWE799 Tuesday, 10/03/17 04:16:58 PM
Re: None
Post #
2412
of 2466 Go
GRCK-Flies High With New Hempoil Acquisition Target Eqova Life Sciences
http://emerginggrowth.com/greycloak-otc-pink-grck-flies-high-new-hempoil-acquisition-target-eqova-life-sciences/
Emerging Growth Stocks
Botanical Oils are one of the fastest growing segments in nutraceuticals
Management Team with superb credentials.
Favorable capital structure
Strategic Investor backstops acquisition
The market reaction to the acquisition of Eqova Life Sciences was very favorable trading up 132% on Friday. The size of the Cannabinoid (CBD) products market is expected to reach $2.1 Billion by 2020 according to the Hemp Business Journal. This means there is still a lot of opportunity for innovative startups like Eqova. When companies enter a market that is growing so large and so fast, entrepreneurs can lose sight of their focus. The pending acquisition of Eqova Life Sciences by Grey Cloak Technology (GRCK) due to close on October 10th seems like an ideal union that will provide capital markets liquidity to a startup company focused on the medical practitioner market. The question on investor’s minds is how well can they execute on their business model and is it viable? After conducting a little due diligence the answer appears to be in the team they assembled. This team seem to be laser focused in targeting the niche market of medical practitioners that buy everything from nutraceuticals to cannabis.
Eqova Management
Patrick Stiles, the head of Eqova Life Sciences, is an industry veteran in the supplement industry. His background is primarily in psychotropic therapies which makes him ideally suited for the hemp oil market. For those that don’t have a dictionary handy, psychotropic means he is an expert in designing supplements that deal with a person’s mental state. He was co-founder and CEO of Zen Life Supplements for over 6 years and was responsible for all facets of the operation including marketing and at its height had upwards of $1 mill in ad budget spent in just digital media. The marketing background he offers the new company is a unique skillset that encompasses a consultative approach to direct marketing in a highly competitive supplement industry. This is exactly what he was doing for years at Zen Life but he had to face the headwinds of distinguishing the products from all the other supplements out there. The laser focus on Hemp Oil allows him to leverage all the positive press surrounding its uses and fold this into an aggressive growth plan that targets medical practitioners. He was also involved in Thrive Science another small startup supplement company. This background and entrepreneurial spirit that he brings to the new company just serves to underscore the old adage that you bet on the jockey not the horse.
He is not alone in this endeavor, Matt Grabau will be responsible for the sales and distribution of the product. Matt is an all-star on his own account and brings a wealth of experience. For the last 12 years, he’s headed up sales for some of the largest practitioner lines of supplements in the country. His team at Rocky Mountain Pro Nutrients focuses on personalized medicines and giving medical practitioners the toolkit they need to help their patients. Him and his direct reports have been selling $5 million annually while dealing with men’s and women’s health issues, immune health, sports nutrition, antioxidants, detoxification, cardiovascular, and blood sugar to name a few.
The convergence of these 2 industry veterans is no mistake because they can leverage their relationships to build a very large distribution force from scratch and effectively manage the growth. It is conceivable that Patrick will be focused on logistics, operations, and marketing while Matt leads the sales channels. They seem to be ramping up sales efforts quite nicely with over 10+ jobs posted on Zip Recruiterand Linked in looking for CBD sales reps. Getting sales seems to be both of these managers forte and that focus to drive sales is what creates the true value in this company.
Exponential Sales Growth Potential
Doing some napkin math it’s conceivable that with 10 sales reps they might be able to do about $1 million per sales representative annually. This metric comes from what an average outside sales pharmaceutical rep could produce to a pharmacy in a given year. This sales team could drive total sales close to $10 mil in the first year. With at least 50% Gross Margins on hemp oil it’s not unreasonable to see $5 mil in gross profit the first year.
Favorable Market Structure
The company is on OTC markets listed under Pink Current Information and fully reporting with the SEC. From the latest 10-Q they had 25,319,572 shares issued and outstanding. Their fraud analytics subsidiary is continuing to produce revenue but it’s uncertain if they are profitable. The salient point about the revenue is that GRCK is not a shell company. The company is active and has been making progress on the balance sheet and has cleaned up some of its convertible debt and went from $405,097 to $349,062 in the past 6 months according to the last quarterly filing. They have been fully reporting since 2015 so a natural progression to look for might be an uplisting, now that money and revenue seem to be in place.
Large Strategic Investor
There was a 13-G filing by Oakmore Opportunity Fund LLP on Sept 26, 2017 where they filed that they owned 4,657,247 shares of common stock or 9.9% of the stock which puts the new share count at 46,619,089. The timing of this filing suggests a couple of things. It appears that they likely bought out the remaining debt from the noteholder and might have put additional capital in the company to scale up operation. Oakmore doesn’t seem to be a very large fund with its only other holding in Wisdom Homes of America, Inc. (WOFA) but it seems they are very selective and that should bode well for GRCK shareholders. It’s not hard to connect that the activity in the past couple of days has been driven by fund interest in a great growth story.
Earnings Growth Acceleration
The details of the deal remain unknown but it’s not hard to conservatively speculate that management might hold has much as 25% percent of the company which could potentially drive the share count as high at 58 million. Assuming share count goes to 58 million, and it might not even be that dilutive because they might structure in some options based on performance investors could be looking at roughly $.16 in eps per share assuming this capital structure and sales momentum. Investor’s should keep in mind that this is a hypothetical scenario and should wait until early October to see what the terms of the deal are and react accordingly.
Investment Summary
GRCK with its acquisition of Eqova Life Sciences might have stuck paydirt. What you essentially have are two industry veterans, powerhouses in their own right, coming together to sell the hottest selling product in the nutraceutical space utilizing their industry acumen and contacts. The question yet to be answered is do they have the right plan to rapidly scale the business? Their industry experience seems to be perfectly aligned to target the commonly ignored practitioner market. A strategic investor with startup capital seems to be in place and the dilution has come to an end setting up the perfect storm for stock appreciation. With potential sales news on the horizon, and the build out of product labels and inventory this could be a fun story to watch unfold. With 46 mil shares outstanding and a market cap of $1.15 mil this seems undervalued given the potential of this team. It’s way too early in the story to set price targets but the earnings potential of this business is amazing compared to the last acquisition target they were looking at when the stock was trading at $.15/share.
GRCK-Flies High With New Hempoil Acquisition Target Eqova Life Sciences
http://emerginggrowth.com/greycloak-otc-pink-grck-flies-high-new-hempoil-acquisition-target-eqova-life-sciences/
Emerging Growth Stocks
Botanical Oils are one of the fastest growing segments in nutraceuticals
Management Team with superb credentials.
Favorable capital structure
Strategic Investor backstops acquisition
The market reaction to the acquisition of Eqova Life Sciences was very favorable trading up 132% on Friday. The size of the Cannabinoid (CBD) products market is expected to reach $2.1 Billion by 2020 according to the Hemp Business Journal. This means there is still a lot of opportunity for innovative startups like Eqova. When companies enter a market that is growing so large and so fast, entrepreneurs can lose sight of their focus. The pending acquisition of Eqova Life Sciences by Grey Cloak Technology (GRCK) due to close on October 10th seems like an ideal union that will provide capital markets liquidity to a startup company focused on the medical practitioner market. The question on investor’s minds is how well can they execute on their business model and is it viable? After conducting a little due diligence the answer appears to be in the team they assembled. This team seem to be laser focused in targeting the niche market of medical practitioners that buy everything from nutraceuticals to cannabis.
Eqova Management
Patrick Stiles, the head of Eqova Life Sciences, is an industry veteran in the supplement industry. His background is primarily in psychotropic therapies which makes him ideally suited for the hemp oil market. For those that don’t have a dictionary handy, psychotropic means he is an expert in designing supplements that deal with a person’s mental state. He was co-founder and CEO of Zen Life Supplements for over 6 years and was responsible for all facets of the operation including marketing and at its height had upwards of $1 mill in ad budget spent in just digital media. The marketing background he offers the new company is a unique skillset that encompasses a consultative approach to direct marketing in a highly competitive supplement industry. This is exactly what he was doing for years at Zen Life but he had to face the headwinds of distinguishing the products from all the other supplements out there. The laser focus on Hemp Oil allows him to leverage all the positive press surrounding its uses and fold this into an aggressive growth plan that targets medical practitioners. He was also involved in Thrive Science another small startup supplement company. This background and entrepreneurial spirit that he brings to the new company just serves to underscore the old adage that you bet on the jockey not the horse.
He is not alone in this endeavor, Matt Grabau will be responsible for the sales and distribution of the product. Matt is an all-star on his own account and brings a wealth of experience. For the last 12 years, he’s headed up sales for some of the largest practitioner lines of supplements in the country. His team at Rocky Mountain Pro Nutrients focuses on personalized medicines and giving medical practitioners the toolkit they need to help their patients. Him and his direct reports have been selling $5 million annually while dealing with men’s and women’s health issues, immune health, sports nutrition, antioxidants, detoxification, cardiovascular, and blood sugar to name a few.
The convergence of these 2 industry veterans is no mistake because they can leverage their relationships to build a very large distribution force from scratch and effectively manage the growth. It is conceivable that Patrick will be focused on logistics, operations, and marketing while Matt leads the sales channels. They seem to be ramping up sales efforts quite nicely with over 10+ jobs posted on Zip Recruiterand Linked in looking for CBD sales reps. Getting sales seems to be both of these managers forte and that focus to drive sales is what creates the true value in this company.
Exponential Sales Growth Potential
Doing some napkin math it’s conceivable that with 10 sales reps they might be able to do about $1 million per sales representative annually. This metric comes from what an average outside sales pharmaceutical rep could produce to a pharmacy in a given year. This sales team could drive total sales close to $10 mil in the first year. With at least 50% Gross Margins on hemp oil it’s not unreasonable to see $5 mil in gross profit the first year.
Favorable Market Structure
The company is on OTC markets listed under Pink Current Information and fully reporting with the SEC. From the latest 10-Q they had 25,319,572 shares issued and outstanding. Their fraud analytics subsidiary is continuing to produce revenue but it’s uncertain if they are profitable. The salient point about the revenue is that GRCK is not a shell company. The company is active and has been making progress on the balance sheet and has cleaned up some of its convertible debt and went from $405,097 to $349,062 in the past 6 months according to the last quarterly filing. They have been fully reporting since 2015 so a natural progression to look for might be an uplisting, now that money and revenue seem to be in place.
Large Strategic Investor
There was a 13-G filing by Oakmore Opportunity Fund LLP on Sept 26, 2017 where they filed that they owned 4,657,247 shares of common stock or 9.9% of the stock which puts the new share count at 46,619,089. The timing of this filing suggests a couple of things. It appears that they likely bought out the remaining debt from the noteholder and might have put additional capital in the company to scale up operation. Oakmore doesn’t seem to be a very large fund with its only other holding in Wisdom Homes of America, Inc. (WOFA) but it seems they are very selective and that should bode well for GRCK shareholders. It’s not hard to connect that the activity in the past couple of days has been driven by fund interest in a great growth story.
Earnings Growth Acceleration
The details of the deal remain unknown but it’s not hard to conservatively speculate that management might hold has much as 25% percent of the company which could potentially drive the share count as high at 58 million. Assuming share count goes to 58 million, and it might not even be that dilutive because they might structure in some options based on performance investors could be looking at roughly $.16 in eps per share assuming this capital structure and sales momentum. Investor’s should keep in mind that this is a hypothetical scenario and should wait until early October to see what the terms of the deal are and react accordingly.
Investment Summary
GRCK with its acquisition of Eqova Life Sciences might have stuck paydirt. What you essentially have are two industry veterans, powerhouses in their own right, coming together to sell the hottest selling product in the nutraceutical space utilizing their industry acumen and contacts. The question yet to be answered is do they have the right plan to rapidly scale the business? Their industry experience seems to be perfectly aligned to target the commonly ignored practitioner market. A strategic investor with startup capital seems to be in place and the dilution has come to an end setting up the perfect storm for stock appreciation. With potential sales news on the horizon, and the build out of product labels and inventory this could be a fun story to watch unfold. With 46 mil shares outstanding and a market cap of $1.15 mil this seems undervalued given the potential of this team. It’s way too early in the story to set price targets but the earnings potential of this business is amazing compared to the last acquisition target they were looking at when the stock was trading at $.15/share.
BITCOIN NEW$ - Government Agencies Adopting Bitcoin and Blockchain Technology
If The U.S. Department of Defence and DARPA are taking an interest within this sector, CCTL could very well have a great year....
https://news.bitcoin.com/government-agencies-want-to-adopt-bitcoin-and-blockchain-technology/?utm_source=OneSignal%20Push&utm_medium=notification&utm_campaign=Push%20Notifications
" Lithium - The New Gasoline"
Goldman Sachs 02.25.2016
"Ignoring Lithium is a dangerous idea for the shrewd investor."
"Citi Research Projects Lithium Battery Market To Be $ 40 Billion by 2020."
"That'a a 10 year growth rate of more than 250 %"
http://www.prnewswire.com/news-releases/this-emerging-lithium-producer-could-disrupt-the-entire-industry-570101771.html
Beneficiaries of The Electric Vehicle Boom"
By Dan Scott - Global Equity Research
Posted On Credit Suisse Website
"Lithium Based Batteries" = "The Salt on The Salad"
- Tesla's Founder and CEO Elon Musk
" Cathodes Form about 30 % of the Battery and Require Lithium....."
" According to Credit Suisse Global Equity and Credit Research Team. Lithium Carbonate demand will Rise from about 200 Kilotons today to over 500 Kilotons in 2015."
https://www.credit-suisse.com/us/en/articles/articles/news-and-expertise/2016/11/en/beneficiaries-of-the-electric-vehicle-boom.html
Beneficiaries of The Electric Vehicle Boom"
By Dan Scott - Global Equity Research
Posted On Credit Suisse Website
"Lithium Based Batteries" = "The Salt on The Salad"
- Tesla's Founder and CEO Elon Musk
" Cathodes Form about 30 % of the Battery and Require Lithium....."
" According to Credit Suisse Global Equity and Credit Research Team. Lithium Carbonate demand will Rise from about 200 Kilotons today to over 500 Kilotons in 2015."
https://www.credit-suisse.com/us/en/articles/articles/news-and-expertise/2016/11/en/beneficiaries-of-the-electric-vehicle-boom.html